SABPrimaryLogoColorRGB900px72ppi.png
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
13 sept. 2024 07h00 HE | SAB Biotherapeutics, Inc.
MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
SAB_Logo.png
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
21 mai 2024 07h15 HE | SAB Biotherapeutics, Inc.
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
SAB_Logo.png
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
20 mai 2024 17h45 HE | SAB Biotherapeutics, Inc.
SAB Biotherapeutics Announces Q1 2024 Financial Results
SAB_Logo.png
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
06 mai 2024 07h15 HE | SAB Biotherapeutics, Inc.
MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
SAB_Logo.png
SAB Biotherapeutics Provides SAB-142 Trial Update
16 avr. 2024 07h15 HE | SAB Biotherapeutics, Inc.
SAB Biotherapeutics provides update on SAB-142 clinical trial for type 1 diabetes
SAB_Logo.png
SAB Biotherapeutics to Present at INNODIA Annual Meeting
08 avr. 2024 07h15 HE | SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. today announced their Chief Medical Officer will share an overview of the SAB-142 clinical development plan at INNODIA.